The nucleotide sequence-was determined for all 22 exons of the insulin receptor gene from three patients with genetic syndromes associated with extreme insulin resistance. In all three patients, insulin resistance was caused by decreased insulin binding to the cell surface. The patient with leprechaunism (leprechaun/Winnipeg) came from a consanguineous pedigree and was homozygous for a missense mutation substituting arginine for His2" in the a-subunit of the insulin receptor. The other two patients were both compound heterozygotes with a nonsense mutation in one allele of the insulin receptor gene, and a missense mutation in the other allele. In the patient with the Rabson-Mendenhall syndrome (patient RM-1), the missense mutation substituted lysine for Asn'5 in the a-subunit. In the patient with type A extreme insulin resistance (patient A-i), the missense mutation substituted serine for Asn462 in the a-subunit. Both nonsense mutations markedly reduced the levels of insulin receptor mRNA transcribed from the alleles with the nonsense mutation as compared to the transcripts from the other allele. The reduction in the level of mRNA would be predicted to greatly reduce the rate at which the truncated receptors would be synthesized. Furthermore, the truncated receptors would be severely impaired in their ability to mediate insulin action. (J. Clin. Invest. 1990. 86:254-264.) 
Introduction
The mechanism of insulin action involves multiple steps, many of which have not been characterized in detail. Defects in any of these steps may give rise to insulin resistance. In as much as the insulin receptor is responsible for mediating the first step in insulin action, the insulin receptor gene is a candidate to be the locus for mutations causing insulin resistance. Indeed, mutations have been identified in the insulin receptor gene in patients with leprechaunism (1-3) and type A extreme insulin resistance (4) (5) (6) (7) (8) .
We have investigated three patients with genetic syndromes associated with extreme insulin resistance, all ofwhom have been reported to have a marked (80-90%) decrease in insulin binding to the cell surface (9) (10) (11) (12) (13) (14) . One patient was homozygous for a missense mutation substituting arginine for His2' in the a-subunit. The other two patients were compound heterozygotes for one allele with a nonsense mutation and one allele with a missense mutation. Both of the missense mutations were also located in the a-subunit: substituting lysine for Asn'5 or serine for Asn 2. Like most premature chain termination mutations in several genes (3, (15) (16) (17) (18) , the two nonsense mutations (at codons 133 and 1000) reduced the level of mRNA transcribed from the mutant allele.
This study supports the growing body of evidence that mutations in the insulin receptor gene are the cause of genetic syndromes associated with extreme insulin resistance such as leprechaunism, type A extreme insulin resistance, and the Rabson-Mendenhall syndrome (1) (2) (3) (4) (5) (6) (7) (8) (19) (20) (21) . The application of the polymerase chain reaction combined with direct sequencing of amplified genomic DNA greatly facilitates determinations of nucleotide sequence and identification of mutations (3, 22, 23) .
Methods
Patients (Table I ). The patient RM-I has the Rabson-Mendenhall syndrome, a genetic syndrome associated with extreme insulin resistance, acanthosis nigricans, dental dysplasia, dystrophic nails, and precocious puberty (12, 24) . Patient A-I has the syndrome of type A extreme insulin resistance associated with acanthosis nigricans and hyperandrogenism (25) . Leprechaun/Winnipeg (26) and leprechaun/ Minn-l (9) had the syndrome of leprechaunism. In addition, we have studied the insulin resistant father of another patient with leprechaunism, leprechaun/Ark-I (1, (27) (28) (29) .
Patients A-l (9), RM-I (12) , and leprechaun/Minn-l (9) had markedly decreased numbers of insulin receptors on the surface of their [3] [4] [5] [6] [7] ase using the patient's genomic DNA as template as described prephoresis through a 1.8% agarose gel and transferred to nylon memviously (3, 32) . Primers were chosen in the introns flanking each exon branes (Schleicher & Schuell, Inc., Keene, NH). The DNA blots were (reference 33 and Table II) . For exon 1, the method was modified to hybridized with 32P-labeled synthetic oligonucleotides that were speminimize technical problems caused by the high GC content of this cific for either the wild-type or mutant sequences (3, 6, 8) . exon (34) (35) (36) (37) (38) (39) (40) . 7-Deaza-dGTP (150 MM) in addition to dGTP (50 AM) Numbering systems for amino acids and nucleotides. We have was included in the reaction mixture to amplify this exon (33, 41 Asn15
Cys208 Arg209 Ser210 amplified genomic DNA (Fig. 1) . The method of direct sequencing has several advantages, among them the ability to determine the sequences of both alleles of the insulin receptor gene simultaneously. At any position where the two alleles differ, two bands will be visible in the sequencing ladder ( Fig.  1, top) ; each of the two bands will have approximately half of the normal intensity.
In this study, we have used this approach to identify mutations in the insulin receptor genes from three patients with genetic forms of insulin resistance. Each patient has two mutant alleles of the insulin receptor gene (Table III, Fig. 2 ): (a) Leprechaun/Winnipeg is a member ofa consanguineous pedigree (26) and is homozygous for a missense mutation substituting arginine (CGC) for histidine (CAC) at codon 209 ( Fig.  1, bottom) . (b) Patient RM-l (12) is a compound heterozygote. In one allele, the patient has a nonsense mutation substituting the opal chain termination codon (TGA) for arginine (CGA) at codon 1,000. In the other allele, there is a missense mutation substituting lysine (AAA) for asparagine (AAC) at codon 15 ( Fig. 1, top) . (c) Patient A-1 (25) is a compound heterozygote. In one allele, the patient has a nonsense mutation substituting the amber chain termination codon (TAG) for tryptophan (TGG) at codon 133. In the other allele, there is a missense mutation substituting serine (AGT) for asparagine ( In addition to the three patients noted above, we have also determined the nucleotide sequence of both alleles of the insulin receptor gene of the father of another patient with leprechaunism (leprechaun/Ark-i). Based on previous studies in which insulin receptor cDNA was cloned from leprechaun/ Ark-I (1), we had concluded that the father had one allele with a nonsense mutation at codon 672. Inasmuch as the father was hyperinsulinemic and insulin resistant (30, 32) , we wished to determine whether heterozygosity for a single mutant allele was sufficient to cause insulin resistance. Therefore, we used the approach of PCR plus direct sequencing to determine whether the father's second allele had a normal sequence. We confirmed our previous conclusion that the father is heterozygous for the nonsense mutation (1, 29) . In addition, the remainder of the sequence determined by this approach was entirely consistent with that which we had determined previously by cDNA cloning (1). Furthermore, we have confirmed that the father's second allele encodes an insulin receptor with a normal amino acid sequence (Table IV) . Thus, the father is a compound heterozygote having one normal allele and one allele with a nonsense mutation.
Expression oftwo alleles ofinsulin receptor gene
Most nonsense mutations are associated with a decrease in the level of mRNA (3, (15) (16) (17) (18) . Nevertheless, it is clear that nonsense mutations can sometimes be associated with normal levels of mRNA. For example, we have previously identified two nonsense mutations in the insulin receptor gene of two patients with leprechaunism: at codons 672 and 897 (1, 3) . The nonsense mutation at codon 672 in the paternal allele of leprechaun/Ark-1 did not appear to decrease the level of insulin receptor mRNA (1) . In contrast, the nonsense mutation at codon 897 in the paternal allele of leprechaun/Minn-l led to a 90% reduction in the level of insulin receptor mRNA (3). Thus, it was of interest to determine the level of mRNA transcribed from the two alleles with nonsense mutations at codons 133 and 1000 in patients A-I and RM-1, respectively. To address this question, we synthesized single-stranded insulin receptor cDNA using reverse transcriptase. Thereafter, the polymerase chain reaction was used to amplify cDNA in the regions spanning the nonsense mutations (nt. 149-548 in patient A-I and nt. 2,773-3,2 10 in patient RM-1). Hybridization with allele-specific oligonucleotide probes was used to determine the level of transcripts from each allele (Fig. 3) . When amplified cDNA from RM-1 was analyzed, both the wild-type sequence and the sequence with the nonsense mutation were detected (Fig. 3, lower left sections) . However, the intensity of the band detected by hybridization with the mutant probe is -90% less than that of the band detected with the wild-type probe (Fig. 3, lower left sections) . In contrast, because the two alleles are present in a 1:1 ratio in genomic DNA, both probes detect bands of approximately equal intensity in Southern blots ofamplified genomic DNA (Fig. 3, upper left sections) . In similar studies, we analyzed the sequence of mRNA at codon 15. The intensity of the band detected by hybridization with the wild-type (Asn"5) probe is -90% less than that ofthe band detected with the probe specific for the Lys'5-mutation (Fig. 2,  lower right sections) . In contrast, because the two alleles are present in a 1:1 ratio in genomic DNA, both probes detect bands of approximately equal intensity in Southern blots of amplified genomic DNA (Fig. 2, upper right sections) . Thus, one can conclude that the level of mRNA transcribed from the 258 Kadowaki, Kadowaki, Rechler, Serrano-Rios, Roth, Gorden, and Taylor rrArv 102 02 frAr%^A12 allele with the nonsense mutation (haplotype, Asn'5/Opall 000) is markedly reduced in cells from patient RM-1 relative to the level of insulin receptor mRNA transcribed from the allele with the missense mutation (haplotype, Lys15/Argl"°°°). In other words, the missense mutation (Lys'5) and nonsense mutation (Opal',) map to different alleles ofthe insulin receptor gene in patient RM-1.
By a similar approach, we demonstrated that the missense mutation (Ser462) and nonsense mutation (Amber'33) map to different alleles ofthe insulin receptor gene in patient A-I (Fig.  4, right S'-Flanking sequence. We have determined the nucleotide sequence of a fragment of genomic DNA extending from the Nco I site at the initiator methionine codon in exon 1 to an Xho I site located 876 bp upstream. The nucleotide sequences of six independent clones from leprechaun/Minn-1 and one clone from a normal subject were identical to the sequence reported by Seino et al. (34) with two exceptions: C instead of G at position -456 and CC instead of CCC at positions -131 through -129. Our sequences at these two positions were identical to those reported by other laboratories (6, (37) (38) (39) (40) . Four independent clones from patient A-I differed at two positions: G instead of A at position -603 and A instead of G at position -500 (Table V) . At both of these positions, the sequence determined in the insulin receptor gene from patient A-I is identical to that originally reported by Araki et al. (37) . The polymorphism at nucleotide -603 is especially interesting because it is located at a consensus sequence for binding of the transcription factor Spi (43) .
Intervening sequence. We have observed six polymorphisms in intervening sequences (Table V) . One of the polymorphisms, located in the 3'-portion of intron 2, involves a variable number (10 vs. 1 1) of TC repeats. The remaining five polymorphisms are caused by single base pair changes. One of these polymorphisms, located in the 5'-portion of intron 8, alters a recognition site for Eco RI (GAA1TC vs. GAA1T7T). As a result, the sequence polymorphism can also be detected as a restriction fragment length polymorphism (RFLP): a 12.0-kb vs. a 9.4-kb band (data not shown). This same RFLP has also been noted in a Japanese patient with extreme insulin resistance (E. Imano, T. Kadowaki, H. Kadowaki, R. Kawamori, and S. I. Taylor, unpublished observations).
f-Untranslated sequence. At nucleotide 4,265, we detected A in one allele of leprechaun/Minn-l. In all other alleles, we have detected G at that position (Table V) .
Discussion
In these investigations, we have identified mutations in the insulin receptor gene in three patients, each with a distinct clinical syndrome associated with extreme insulin resistance. The two patients with the Rabson-Mendenhall syndrome (RM-1) and type A extreme insulin resistance (A-1) are compound heterozygotes for two different mutant alleles (Table  III ) that impair receptor function by different mechanisms. Thus, these two patients resemble two previously reported patients with leprechaunism (leprechaun/Ark-I and leprechaun/ Minn-1) who were also compound heterozygotes. Interestingly, like the present patients (A-I and RM-1), both of these (Table III) . Previously, three other consanguineous pedigrees have been described in which the affected individuals were homozygous for a mutation in the insulin receptor gene: one kindred with leprechaunism (2) and two kindreds with type A extreme insulin resistance (4, 6).
Nonsense mutations decrease levels of insulin receptor mRNA Two of the patients (A-1 and RM-1) in the present study were heterozygous for nonsense mutations in the insulin receptor gene. Previously, we have identified two nonsense mutations in the insulin receptor genes of two patients with leprechaunism (1, 3) . In leprechaun/Minn-1, as with patients A-1 and RM-1, the nonsense mutation is associated with a marked decrease in the level of mRNA transcribed from that allele (3) . The present studies demonstrate the advantage of using genomic DNA rather than mRNA as template. In patients A-1 and RM-1, mRNA transcribed from the alleles with the nonsense mutations is present in very low level relative to mRNA transcribed from the alleles with the missense mutation. Thus, it is unlikely that we would have detected the nonsense mutations if we had used a combination of reverse transcriptase and PCR to amplify mRNA.
In patient A-1, a nonsense mutation was identified at codon 133 ofexon 2 in one allele ofthe insulin receptor gene: a tryptophan codon (TGG) was replaced by an amber stop codon (TAG). Thus, the truncated receptor is a short fragment that would not be expected to be functional. In patient RM-1, a nonsense mutation was identified at codon 1,000 in exon 17 in one allele of the insulin receptor gene: an arginine codon (CGA) was replaced by an opal stop codon (TGA). This nonsense mutation truncates the protein just before the ATP binding site of the tyrosine kinase domain. This truncated protein retains the extracellular domain as well as the transmembrane anchor. Thus, one might predict that the truncated receptor would retain the ability to bind insulin and would be expressed at the cell surface (44, 45) . However, we obtained data that this nonsense mutation decreases the level of mRNA by -90% so that little of the truncated receptor is synthesized. These conclusions are consistent with our previous investigations of receptor biosynthesis in both patients' EBV-transformed lymphocytes. In those studies, we did not detect a truncated receptor molecule (1 1, 13) .
Taira et al. (7) have described two patients (a mother and daughter) who are heterozygous for a deletion in the insulin receptor gene. Based on the nucleotide sequence of genomic DNA, they predict that the mRNA would encode a fusion protein that has an open reading frame for an additional 65 amino acids after the deletion break point at codon 1012. Data were not presented to indicate whether it is possible to detect mRNA transcribed from this mutant allele or the fusion protein it would encode. Nevertheless, it is possible that the abnormal stop codon introduced by the deletion would result in a low level of mRNA in much the same way we have observed with nonsense mutations.
Missense mutations in the insulin receptor gene Lys'5 and Arg209 mutations. When the Lys'5 and Arg209 mutant receptors were expressed by transfection in NIH-3T3 cells (T. Kadowaki, H. Kadowaki, and S. I. Taylor, unpublished observations), both produced phenotypes very similar to that caused by the Val382 mutation described by Accili et al. (6) . All three mutations impair posttranslational processing of the high mannose form of N-linked carbohydrate to complex carbohydrate. Furthermore, all three mutations impair the transport of the receptor to the cell surface. It seems likely that these observations can be explained if the mutant receptors are im-paired in their ability to be transported through the endoplasmic reticulum and Golgi. Presumably, most of the patients' receptors fail to be transported to the compartment of the Golgi where the enzymes exist for processing of the N-linked carbohydrate. It is only a minority of the mutant receptors that undergo normal maturation of the N-linked oligosaccharide, and it is only this minority of receptor molecules that are transported to the cell surface for insertion in the plasma membrane.
For normal intracellular transport of membrane proteins such as the insulin receptor to occur, it is necessary that the protein fold correctly within the rough endoplasmic reticulum and/or Golgi to form the normal three-dimensional structure. Mutations that disrupt the normal folding of the receptor can cause the phenotype of defective posttranslational processing and impaired intracellular transport, thereby reducing the number of insulin receptors on the cell surface. In this regard, it is relevant that Asn'5 has been proposed to be the initial amino acid at the NH2 terminus of a predicted a-helical domain of the insulin receptor (46) . Furthermore, asparagine is conserved in this position in the IGF-l receptor (47, 48) and replaced by serine in the homologous position of the insulin receptor-related protein (49) . As emphasized by Richardson and Richardson (50) , asparagine and serine are the amino acids that are preferentially selected to be located at the "Ncap" position; i.e., at the NH2-terminal initiation of an a-helical domain. In contrast, in as much as lysine is seldom present at the N-cap of an a-helical domain (50), the Lys'5 mutation might be predicted to disrupt the a-helix.
His209 is located in the cysteine-rich domain (amino acids 155-312) of the insulin receptor a-subunit. Comparison of the amino acid sequences of the cysteine-rich domains of several receptors demonstrates that the amino acid residue His29 is highly conserved. There are seventeen cysteine residues that are conserved in the cysteine-rich domain of the human insulin receptor as well as the homologous domains of ten other receptors including the human and rat insulin-like growth factor-1 receptors (47, 48) , the human and guinea pig insulin receptor-related proteins (49), the human, chicken, and drosophila epidermal growth factor receptors (52-54), the human and rat c-erb B-2 proteins (55, 56) , and the human c-erb B-3 protein (57) . Of the remaining 141 amino acids in the cysteine-rich domain, there are only two other amino acids that are identically conserved in all eleven receptors: His2" and pro219:
Cys--* * -Cys-CysHis-X-X-CysX-X-X-Cys-X-X-Pro-* * * -Cys. The perfect conservation of His209 strongly suggests that it plays an important role in maintaining normal receptor structure.
Ser462-mutation. The amino acid Asn462 is conserved in all of the known sequences of the insulin receptor ( 1-3, 6, 16, 19, 33-36 , 41, 5 1) and also in two homologous proteins, the IGF-1 receptor (48) and the insulin-receptor related protein (50) .
Moreover, Asn462 is nearby Lys4, the residue that was the locus of the missense mutation we have detected previously in the maternal allele of the insulin receptor gene of leprechaun/ Ark-1 (1) . When the Ser462 mutant receptor was expressed by transfection in NIH-3T3 cells (T. Kadowaki, H. Kadowaki, and S. I. Taylor, unpublished observations), it produced a phenotype very similar to that caused by the Glu' mutation described previously (1) . Both mutations (Glu"0 and Ser462) decrease the sensitivity of the receptor to changes in pH. Thus, it seems likely that both mutations cause insulin resistance by similar mechanisms.
Polymorphisms ofthe insulin receptor gene
The amino acid sequence of the insulin receptor is conserved to a remarkable degree. Indeed, there are no confirmed examples of amino acid sequence polymorphisms in normal insulin receptors although several variant amino acids have been reported in individual cDNA clones (35, 36) . It is possible that all of the reported amino acid polymorphisms result from cloning artifacts (19, 33, 34) . Nevertheless, a number of silent polymorphisms have been identified in the protein coding sequence as a result ofalternate codon use (Table IV) and also in the sequences of several of the introns (Table V) What determines which syndrome a patient will develop? Because the clinical syndromes do not correlate with the type of mutation, it seems most likely that it is the severity of insulin resistance that determines the clinical manifestations. For example, patients with leprechaunism appear to have the most extreme degree of insulin resistance. All of the patients with leprechaunism have had two mutant alleles of the insulin receptor gene; two were compound heterozygotes (1, 3) and two were homozygotes (2; this report). Some patients with type A extreme insulin resistance have also been reported to have two mutant alleles: patient A-1 who is a compound heterozygote as well as two sisters in each of two consanguineous pedigrees, all ofwhom were homozygous for mutations in the insulin receptor gene (4, 6) . However, some patients with type A extreme insulin resistance have appeared to be heterozygous for a single mutant allele of the insulin receptor gene (5, 7, 8) . As exemplified by the comparison between leprechaun/Ark-I and her father (1), the degree of insulin resistance observed in heterozygotes is less severe than the insulin resistance in homozygotes and compound heterozygotes. As we have shown in the present work, the father of leprechaun/Ark-I is heterozygous for a nonsense mutation in the insulin receptor gene while his other allele encodes a normal receptor. The presence of a second mutant allele in the daughter is the cause of her more severe degree of insulin resistance in addition to the multiple phenotypic abnormalities associated with the syndrome of leprechaunism (1, 30, 32) . Similarly, the mother of leprechaun/Winnipeg, an obligate heterozygote for the Arg9 mutation, is insulin resistant and hyperinsulinemic (29) . Thus, although the phenotype ofleprechaunism is recessive, the phenotype of insulin resistance caused by the Arg9 mutation is inherited in a codominant fashion.
In conclusion, at least 13 point mutations have been identified in the insulin receptor gene (Fig. 2) (1-8, 19-21 ). These mutations provide insights into structure-function relationships ofthe insulin receptor and the molecular pathogenesis of genetic syndromes associated with extreme insulin resistance. The application of the polymerase chain reaction combined with direct sequencing of amplified DNA greatly facilitates identification of mutations. Thus, it will be possible to investigate a sufficiently large number of patients to estimate the frequency of mutations in the insulin receptor gene, and to determine whether mutations in this gene contribute to the pathogenesis of common diseases such as noninsulin-dependent diabetes mellitus.
